72 articles found
New York's Governor signed a law letting the state's mental health and addiction agencies set a single licensing standard for integrated care of co-occurring disorders.
FDA sets a September 14 public hearing on therapeutic psychedelics and finalizes its first clinical trial guidance for psilocybin, LSD and MDMA.
SAMHSA announces over $281 million in funding opportunities across 15 grant programs to expand medication-assisted treatment, overdose prevention, and mental health services nationwide.
CDC informs state and local health programs they must agree to new Trump administration priorities within days, including deprioritizing harm reduction and housing-first strategies proven to reduce drug overdoses.
Compass Pathways' COMP360 psilocybin therapy could receive FDA approval by late 2026, marking a historic milestone for psychedelic medicine and offering new hope for treatment-resistant depression.
Aptihealth settles for $300,000 after billing Medicaid for no-show appointments as DOJ charges 455 defendants in $6.5 billion health care fraud crackdown targeting telehealth sector.
Michigan awards $3.75 million in opioid settlement grants to 12 organizations focused on youth substance use prevention, targeting early intervention to reduce lifetime addiction risk.
The funding package includes $96 million for the new STREETS program and $612 million for expanded behavioral health services, marking a significant federal investment in street-based outreach and community-wide recovery support.
New FAIR Health data reveals mental health conditions account for 52% of all telehealth diagnoses in Q1 2026, ranking as the top diagnostic category in every U.S. region and every age group including children under 10.
New AI screening and multi-layer approval process creates unprecedented backlog affecting opioid treatment, suicide prevention, and disease surveillance programs nationwide.
Hundreds of addiction and mental health service providers received termination notices Tuesday night, only to have funding restored Wednesday after swift advocacy response.
Secretary Kennedy unveils $96 million STREETS program and $612 million in additional grants targeting substance use disorders, mental health crises, and homelessness under the Great American Recovery Initiative.
Eight new grant programs target addiction prevention, child trauma, suicide prevention, and mental illness as part of federal behavioral health investment.
Federal funding boost aims to strengthen nation's mental health crisis response system as 988 Lifeline surpasses 25 million contacts since launch
Psychiatric Urgent Care of Huntsville opens as North Alabama's first same-day mental health facility, offering immediate access to psychiatric care and telemedicine services statewide
The Department of Veterans Affairs begins first government-sponsored study of MDMA-assisted therapy, enrolling 80 veterans in groundbreaking research on psychedelic treatment for co-occurring conditions.
FDA grants Breakthrough Therapy designation to LSD d-tartrate for generalized anxiety disorder, accelerating development of the first LSD-based psychiatric treatment and signaling regulatory openness to psychedelic therapies.
Research reveals animal-assisted therapy reduces cravings, lowers cortisol, and improves treatment retention. As recovery programs increasingly incorporate four-legged companions, science backs what many in sobriety have long known.
Stanford-led research shows low-dose buprenorphine after ketamine infusion extends anti-suicidal benefits from days to weeks, offering new hope for high-risk patients.
Louisiana legislature moves to authorize state-funded research into ibogaine, psilocybin, and MDMA for treating substance use disorders and PTSD, joining growing national movement.
New Jonesboro facility addresses critical treatment gap in one of Georgia's most underserved regions, offering medically supervised detox and residential care amid rising overdose rates.
Ohio's Ibogaine Treatment Study Committee convenes to explore clinical trials for ibogaine-assisted therapy, spurred by Trump's executive order accelerating psychedelic research and veteran advocacy.
University of California Davis scientists create new amino acid-based compounds that activate serotonin receptors for mental health benefits without causing hallucinations, potentially revolutionizing addiction and depression therapy.
Minnesota lawmakers vote 114-15 to legalize regulated psilocybin-assisted therapy, making the state the fourth in the nation to authorize supervised psychedelic treatment for mental health and substance use disorders.
White House releases ambitious 195-page drug control strategy calling for easier treatment access, but administration's funding cuts and policy shifts threaten implementation.
Historic expansion of Wisconsin's oldest women's addiction treatment facility addresses critical waitlist of 100+ people, funded by opioid settlement dollars and private philanthropy.
New Hope Valley facility offers residential detox, trauma therapy, and holistic wellness for Alaska's veterans and active-duty members in a state with the highest per-capita veteran population.
Colorado classrooms are embracing harm reduction strategies and naloxone training, moving away from decades of abstinence-only messaging as fentanyl crisis reshapes youth drug education.
FDA awards priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies targeting treatment-resistant depression and PTSD.
New research published in JAMA shows the 988 suicide crisis hotline is associated with significant reductions in suicide deaths among young people, with states showing highest call volume experiencing the greatest declines.
UC San Diego and SDSU study of 2.8 million students finds local flavor bans reduce e-cigarette use by 20% with no increase in cigarette smoking, challenging industry arguments.
Wake Forest research reveals e-cigarette taxes reduced vaping among heterosexual teens by 3-4 percentage points, yet had no effect on LGBQ youth who use nicotine to cope with bullying and emotional distress.
JAMA research letter reveals 24.3% decline in long-term opioid therapy from 2015-2023, even as co-prescribing with gabapentinoids rises sharply, raising new safety concerns for chronic pain patients.
New ASAM Criteria volume establishes dedicated clinical standards for youth SUD treatment, emphasizing brain development, family engagement, and integrated mental health care
BMJ study of 2.5 million Medicaid births finds children exposed to buprenorphine in utero have no greater risk of ADHD, autism, or other neurodevelopmental disorders compared to methadone exposure.
Flow Neuroscience's transcranial direct current stimulation device becomes first prescription brain stimulation therapy available for home use, offering new option for treatment-resistant depression
President Trump signs executive order directing FDA to fast-track psychedelic research, provides $50 million for ibogaine studies, and opens Right to Try pathway for patients with treatment-resistant mental illness.
Advocates press Congress to expand Veterans Treatment Courts and restore VA benefits access for incarcerated veterans struggling with service-connected mental health and substance use disorders
More than 200 residents protest proposed 122-bed addiction treatment facility funded by California's Proposition 1, highlighting tensions between statewide mental health expansion and neighborhood concerns
New research in Journal of Psychiatric Research reveals individuals with opioid use disorder face 1.88 to 4.17 times greater odds of suicidal thoughts, with moderate cases showing highest attempt rates.
ONDCP, SAMHSA and HUD launch two-day summit to develop national toolkit for treating substance use disorders among homeless individuals, marking a shift toward integrated care models
Food and Drug Administration issues complete response letter rejecting Lykos Therapeutics' MDMA-assisted therapy for PTSD, demanding additional clinical trials despite promising efficacy data.
Intravenous DMT reduced depressive symptoms within a week in Phase IIa trial, with effects lasting up to three months, according to study published in Nature Medicine.
House roundtable examines paradox of doubled treatment access, 241% spending increase while depression and suicide reach historic highs. Youth antidepressant prescriptions jump 63%.
Longleaf Lodge launches with 50 residential and 10 detox beds, addressing Alabama's crisis where 19% need substance use treatment but only 5% receive it. Integrated care model tackles co-occurring conditions as wait times stretch weeks to months.
Mississippi, Tennessee, Texas, West Virginia, Oklahoma, and Missouri are coordinating clinical trials of ibogaine—a Schedule I psychedelic—for opioid addiction and PTSD despite federal restrictions.
New report profiles eight alternative mental health crisis programs removing police from response while Trump administration restructuring threatens federal funding infrastructure.
Federal agency proposes expanding community health workers and peer support specialists in rural areas where 60% of Americans lack access to mental health and addiction treatment services.
American Society of Addiction Medicine releases first comprehensive update to youth substance use disorder treatment standards in over a decade, addressing telehealth, trauma-informed care, and medication access.
State officials unveil plan to restructure troubled mental health agency, potentially dissolving it and shifting control to Department of Health as providers struggle with service cuts.
Swedish registry analysis of 100,000 individuals finds GLP-1 medications reduce depression by 44%, anxiety by 38%, and substance use disorders by 47%.
Oregon and Colorado lead regulated psilocybin therapy programs as research shows promise for depression, PTSD, and addiction. Personal stories reveal profound results.
Eastern Shoshone Tribal Health launches Wyoming's first harm reduction vending machines offering free naloxone, fentanyl test strips, and suicide prevention tools through anonymous PIN access to address overdose crisis on Wind River Reservation.
Mayor Daniel Lurie announces Proposition 1 funding for 100 new psychiatric and addiction treatment beds across three sites, even as the city faces $900 million deficit and federal funding cuts.
Parents who lost children to overdoses are urging Pennsylvania to use settlement money to create a comprehensive bereavement support system modeled on Philadelphia's Philly HEALs program.
New Oregon laws streamline licensing, strengthen workplace safety, and expand access to mental health and addiction services amid one of the nation's worst provider shortages
University of Arizona trial finds 73% of participants responded to multiple psilocybin sessions, with 40% achieving remission from obsessive-compulsive disorder symptoms lasting six months.
Lawmakers push package of reforms including 988 funding, treatment bed registry, and insurance coverage mandates as state struggles to meet crisis response needs.
Indiana city's first round of settlement funding prioritizes community organizations meeting people at every stage of recovery, including grief counseling for families navigating substance use loss.
Minnesota lawmakers approved HF 2906, creating a state-regulated psilocybin therapy pilot program with patient caps and bipartisan backing, joining Oregon and Colorado.
Federal judge's ruling forces Education Department to restore funding for 120 school mental health projects, extending support through June 2026 as legal battle continues.
JAMA Network Open study analyzing Medicare records shows specialists using telemedicine heavily saw only 0.9% more rural patients while treating 3.6% fewer new patients overall.
Federal agency opens funding applications for children's mental health services, suicide prevention frameworks, and assisted outpatient treatment programs as part of broader recovery initiative.
Governor Newsom awards funding to 28 regions while launching accountability system recognizing 'CARE Champions' and placing underperforming counties in intensive support program.
While Mississippi sits on over $400 million in opioid settlement funds, the state has spent almost none of it on treatment or family services — even as it leads the nation in children living with grandparents and foster care tied to parental substance use.
New research identifies myelin remodeling as the missing link between short-term psychedelic experiences and long-term PTSD relief, shifting focus from neurons to oligodendrocytes.
State legislators advance $5.7 million appropriation to sustain 988 Mental Health Lifeline after federal funding expires in September, citing success in diverting crisis calls from emergency services.
Missouri's Veterans Mental Health Innovation Act would fund FDA ibogaine clinical trials for opioid use disorder and traumatic brain injury, joining Texas and Arizona in breakthrough therapy research.
State programs like Project Nurture combine prenatal care, substance use treatment, and peer support after Oregon data showed mental health and SUD led pregnancy-related deaths.
The Maternal Overdose Matters Initiative delivered naloxone kits to over 2,500 families at 107 hospitals, helping reverse a crisis where overdose became the leading cause of maternal mortality statewide.
Imperial College London study published in Nature finds that a single 30-minute DMT session with therapeutic support reduced depressive symptoms more effectively than placebo, marking another step forward for psychedelic-assisted mental health treatment.
Senate Bill 2749 passes committee with unanimous vote, expanding Illinois' addiction treatment framework to include problem gambling and mandating new prevention and recovery services statewide.